The Orphan Drug Act and the Development of Stem Cell-Based Products for Rare Diseases

descriptionPublicationkeyboard_double_arrow_right Article 01 Sep 2010 English Publisher:Elsevier BVJournal:Cell Stem Cell, volume 7, pages 283-287 (issn: 1934-5909,

Copyright policy )

Authors: Freeman, Scott N.; Burke, Kathryn A.; Imoisili, Menfo A.; Coté, Timothy R.;

doi: 10.1016/j.stem.2010.08.003

pmid: 20804965

The Orphan Drug Act and the Development of Stem Cell-Based Products for Rare Diseases

- Summary
- Subjects
- Metrics

Abstract

The Orphan Drug Act encourages the development of products for rare diseases and conditions. Many conditions that stand to benefit from stem cell-based products are rare diseases. We address the Orphan Drug Act in relation to the development of stem cell-based products.

Related Organizations

United States Food and Drug Administration
United States

Keywords

Drug Industry, Orphan Drug Production, United States Food and Drug Administration, Stem Cells, Cell Biology, United States, Government Programs, Rare Diseases, Genetics, Molecular Medicine, Stem Cell Transplantation

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	6
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%